Raquel Hontecillas1, Josep Bassaganya-Riera. 1. Nutritional Immunology and Molecular Medicine Laboratory, Center for Modeling Immunity to Enteric Pathogens, Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, Virginia, 24060, United States of America.
Abstract
BACKGROUND & AIMS: Dietary abscisic acid (ABA) has shown efficacy in ameliorating experimental IBD in mice through mechanisms requiring expression of peroxisome proliferator activated-receptor γ (PPAR γ) in immune cells. The goal of this study was to determine whether PPAR γ expression in colonic epithelial cells is required for the anti-inflammatory actions of ABA. METHODS: Conditional knockout mice expressing a transgenic recombinase in intestinal epithelial cells under the control of a villin promoter (PPAR γ flfl; Villin Cre+ or VC+) with defective expression of PPAR γ in intestinal cells (IEC) and PPAR γ-expressing wild type (PPAR γ flfl; Villin Cre- or VC-) mice in a C57BL/6 background were fed diets with and without ABA (0.1 g/kg) for 35 days and challenged with 2.5% dextran sodium sulfate (DSS) in the drinking water for 7 days. Clinical disease severity was assessed daily and colonic lesions on day 7 through macroscopic and histopathological examination. Immune cell phenotypes were examined systemically and at the mesenteric lymph nodes (MLN). Epithelial gene expression was assayed in the colon. RESULTS: Dietary ABA-supplementation prevented colitis, reduced disease severity, improved colonic histopathology, and upregulated epithelial lanthionine synthetase C-like protein 2 (LANCL2) expression in VC+ mice. Dietary ABA significantly increased the percentages of MLN CD4+IL-10+ T cells, and blood CD4+CD25+FoxP3+ T cells and CD8+IL-10+ T cells. CONCLUSION: Expression of PPAR γ in IECs was not required for the anti-inflammatory efficacy of ABA in IBD. LANCL2 in IECs and T cell-derived IL-10 may be implicated in the mechanism underlying ABA's immune modulatory activity in IBD.
BACKGROUND & AIMS: Dietary abscisic acid (ABA) has shown efficacy in ameliorating experimental IBD in mice through mechanisms requiring expression of peroxisome proliferator activated-receptor γ (PPAR γ) in immune cells. The goal of this study was to determine whether PPAR γ expression in colonic epithelial cells is required for the anti-inflammatory actions of ABA. METHODS: Conditional knockout mice expressing a transgenic recombinase in intestinal epithelial cells under the control of a villin promoter (PPAR γ flfl; Villin Cre+ or VC+) with defective expression of PPAR γ in intestinal cells (IEC) and PPAR γ-expressing wild type (PPAR γ flfl; Villin Cre- or VC-) mice in a C57BL/6 background were fed diets with and without ABA (0.1 g/kg) for 35 days and challenged with 2.5% dextran sodium sulfate (DSS) in the drinking water for 7 days. Clinical disease severity was assessed daily and colonic lesions on day 7 through macroscopic and histopathological examination. Immune cell phenotypes were examined systemically and at the mesenteric lymph nodes (MLN). Epithelial gene expression was assayed in the colon. RESULTS: Dietary ABA-supplementation prevented colitis, reduced disease severity, improved colonic histopathology, and upregulated epithelial lanthionine synthetase C-like protein 2 (LANCL2) expression in VC+ mice. Dietary ABA significantly increased the percentages of MLN CD4+IL-10+ T cells, and blood CD4+CD25+FoxP3+ T cells and CD8+IL-10+ T cells. CONCLUSION: Expression of PPAR γ in IECs was not required for the anti-inflammatory efficacy of ABA in IBD. LANCL2 in IECs and T cell-derived IL-10 may be implicated in the mechanism underlying ABA's immune modulatory activity in IBD.
Authors: Josep Bassaganya-Riera; Amir J Guri; Alexis M Noble; Kathryn A Reynolds; Jennifer King; Cynthia M Wood; Michael Ashby; Deshanie Rai; Raquel Hontecillas Journal: Am J Clin Nutr Date: 2007-03 Impact factor: 7.045
Authors: Josep Bassaganya-Riera; Monica Viladomiu; Mireia Pedragosa; Claudio De Simone; Adria Carbo; Rustem Shaykhutdinov; Christian Jobin; Janelle C Arthur; Benjamin A Corl; Hans Vogel; Martin Storr; Raquel Hontecillas Journal: PLoS One Date: 2012-02-21 Impact factor: 3.752
Authors: Elizabeth K K Glennon; L Garry Adams; Derrick R Hicks; Katayoon Dehesh; Shirley Luckhart Journal: Am J Trop Med Hyg Date: 2016-03-21 Impact factor: 2.345
Authors: Younghun Jung; Frank C Cackowski; Kenji Yumoto; Ann M Decker; Yu Wang; Megan Hotchkin; Eunsohl Lee; Laura Buttitta; Russell S Taichman Journal: Neoplasia Date: 2020-12-06 Impact factor: 5.715
Authors: Gajanan D Katkar; Ibrahim M Sayed; Mahitha Shree Anandachar; Vanessa Castillo; Eleadah Vidales; Daniel Toobian; Fatima Usmani; Joseph R Sawires; Geoffray Leriche; Jerry Yang; William J Sandborn; Soumita Das; Debashis Sahoo; Pradipta Ghosh Journal: Commun Biol Date: 2022-03-14